Biotech milestones preview (1): GENZ

One of the important rituals that biotech investors must follow is diligently following the drug trial events and milestones. As I have noticed that many new members have joined FilthyRich group, I thought I would summarize the markets for all six companies and lists rough time frame for the important clinical trial/FDA filing events. Today I will write about GENZ and PDLI in two separate messages. Tomorrow, I will highlight AMGN and ISIS. Finally the day after tomorrow, I will go over CELG and ALNY. The information source is from Lehman reports published on Jan 5th, which complies the all the important events for more than 100 biotech companies. If you are interested in this report, email me via investorhives.com mail and I would be happy to share the report with you. So far, you have noticed that I talked more about CELG and AMGN in my articles. But I will promise that I will write more detailed articles about GENZ, PDLI, ISIS, and ALNY.

GENZ

Description.
Large cap biotech that is diverse with multiple business units encompassing six therapeutic categories: lysosomal storage diseases (LSDs), genetics/diagnostics, orthopedics/biomaterials, renal/endocrinology, transplant & immune disease, and oncology. Key products include: enzyme replacement therapies for LSDs, including Cerezyme for Gaucher's disease, Fabrazyme for Fabry disease, Aldurazyme for Hurler Scheie disease, and Myozyme for Pompe disease. Renagel is a phosphate binder marketed for end-stage renal disease (ESRD) and Hectorol (doxercalciferol) is a pro-hormone vitamin D2 analog for the treatment of secondary hyperparathyroidism in CKD and ESRD. Synvisc is an injectable hyaluronic acid based product marketed for relief of mild to moderate knee pain related to osteoarthritis. Thymoglobulin, an immunosuppressive polyclonal antibody, and Lymphoglobuline are marketed for acute renal transplant rejection. Acquisition of Ilex Oncology in 2004 bought Campath for chronic lymphocytic leukemia (CLL) and Clolar for pediatric acute lymphoblastic leukemia (ALL).

Milestone Events.
1Q07: DX-88 topline results from partner DYAX's EDEMA 3 phase III trial in HAE. 1Q07 Campath phase III PFS data in 1st-line B-CLL. 1H07: File for approval of sevelamer carbonate in CKD, powder form. 1H07: Myozyme data in late-onset Pompe's disease. 1H07: Tolevamer phase III data in clostridium difficile-associated diarrhea. 1H07: Synvisc launch in the US for use in the hip.

My Take.
King of special niche markets. Steady outlook with 15% topline growth potential over next 5 years. Offers both the reasonable growth rate and PE. Special gift at current price. Solid buy with $85 PT


The current stocks in that I cover are: Filthy Rich Tech ideas (comprised of Openwave, Avid Technology, Tivo, IBM, and Research in Motion), Filthy Rich Biotech ideas (comprised of Amgen, Celgene, Genzyme, Isis pharmaceuticals, Alnylam pharmaceutical, and Protein Design Lab), Filthy Rich Financial ideas (JP Morgan and Goldman Sachs), Filthy Rich China ideas (Focus Media Holding and Ctrip.com), Filthy Rich Transportation ideas ( American Airline and Southwest Airline), and Filthy Rich Specialty Retail ideas (Peet's coffee)

Please check out the archives for past posting on individual stocks. Also analysis is available at www.investorhives.com under FilthyRich hive. Thank you for visiting my blog.